Peer-influenced content. Sources you trust. No registration required. This is HCN.
Clinical Advances in Hematology & Oncology
This interview reviews the implications of three recent studies — KEYNOTE-158, EMPOWER, KEYNOTE-826 — on immunotherapy in cervical cancer. In addition to the compelling connection between cervical cancer and the immune system, and therefore the interest in immunotherapy for cervical cancer, immunotherapy offers some key advantages over chemotherapy in this setting. It benefits patients with previous radiation as much as it benefits patients who are radiotherapy-naïve and it is less associated with the formation of fistulas than chemotherapy.
Oncology, Medical August 2nd 2022
ReachMD
Offering 0.25 credits, this 30-minute CME program discusses the new cervical cancer screening guidelines recently published by both the American Society for Colonoscopy and Cervical Pathology (ASCCP) and the American Cancer Society (ACS).
Obstetrics & Gynecology July 13th 2022
MDLinx
‘Bikini medicine’ (see the Boston Globe article) is an outdated, sexist idea that men and women should be cared for similarly — dubbed as such due to the mistaken belief that women’s health only differs in the parts of women that bikinis cover. A ridiculous notion, considering that cardiovascular disease, osteoporosis, and autoimmune diseases affect women differently than men. Last time we checked, the bikini doesn’t cover any of them.
Cardiology July 13th 2022
Northwestern Medicine
Blocking expression of FOXK2 in cancer stem cells inhibited growth of these cells, reducing their so-called “stemness,” making them more like normal cells.
Obstetrics & Gynecology May 11th 2022
Dana-Farber Cancer Institute
Mirvetuximab soravtansine generated an objective response in nearly 1/3 of patients participating. That compares with response rates in the single digits for current treatments in patients whose ovarian cancer doesn’t respond to platinum-based chemotherapy.
Journal of Clinical Oncology
This editorial reflects on the work by Lei and colleagues in teasing out hrHPV-negative vs. positive ovarian cancers with a 15-year follow up. But what to do with the knowledge?